Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 12 | 2024 | 957 | 1.590 |
Why?
|
| Liver Neoplasms | 12 | 2024 | 1386 | 1.420 |
Why?
|
| Liver Cirrhosis | 12 | 2024 | 824 | 1.130 |
Why?
|
| Liver Transplantation | 6 | 2020 | 1033 | 0.770 |
Why?
|
| Hepatitis C | 4 | 2023 | 368 | 0.710 |
Why?
|
| Alcoholic Beverages | 1 | 2019 | 17 | 0.650 |
Why?
|
| End Stage Liver Disease | 3 | 2018 | 178 | 0.640 |
Why?
|
| Religion | 1 | 2019 | 49 | 0.630 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 336 | 0.610 |
Why?
|
| Alcohol Drinking | 2 | 2024 | 331 | 0.590 |
Why?
|
| Hepacivirus | 3 | 2016 | 242 | 0.560 |
Why?
|
| Liver Diseases | 2 | 2018 | 384 | 0.560 |
Why?
|
| Alcoholism | 1 | 2019 | 229 | 0.540 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 142 | 0.500 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 88 | 0.500 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 14 | 0.490 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 54 | 0.470 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 80 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2016 | 736 | 0.420 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 57 | 0.410 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 427 | 0.330 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 386 | 0.300 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2008 | 64 | 0.290 |
Why?
|
| Veterans | 1 | 2018 | 1711 | 0.280 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 220 | 0.260 |
Why?
|
| Quality Improvement | 2 | 2022 | 620 | 0.250 |
Why?
|
| Prospective Studies | 9 | 2024 | 5965 | 0.220 |
Why?
|
| Lipase | 1 | 2024 | 83 | 0.220 |
Why?
|
| alpha-Fetoproteins | 1 | 2024 | 136 | 0.220 |
Why?
|
| Risk Factors | 10 | 2024 | 9864 | 0.220 |
Why?
|
| Humans | 26 | 2024 | 122120 | 0.210 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 236 | 0.200 |
Why?
|
| Graft Survival | 2 | 2014 | 522 | 0.200 |
Why?
|
| Middle Aged | 13 | 2024 | 25538 | 0.180 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2020 | 45 | 0.170 |
Why?
|
| Program Development | 1 | 2020 | 189 | 0.170 |
Why?
|
| United States | 4 | 2024 | 10459 | 0.160 |
Why?
|
| History, 15th Century | 1 | 2019 | 13 | 0.160 |
Why?
|
| History, Medieval | 1 | 2019 | 26 | 0.160 |
Why?
|
| History, 16th Century | 1 | 2019 | 27 | 0.160 |
Why?
|
| History, Ancient | 1 | 2019 | 54 | 0.160 |
Why?
|
| Pentanoic Acids | 1 | 2018 | 3 | 0.160 |
Why?
|
| Caspase Inhibitors | 1 | 2018 | 29 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2020 | 181 | 0.160 |
Why?
|
| Obesity | 3 | 2024 | 1946 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 119 | 0.150 |
Why?
|
| Cystatin C | 1 | 2018 | 49 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 39 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3045 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1629 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2016 | 13 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2024 | 1521 | 0.130 |
Why?
|
| Male | 15 | 2024 | 59429 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 539 | 0.130 |
Why?
|
| Female | 16 | 2024 | 64764 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 232 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2016 | 162 | 0.120 |
Why?
|
| Aged | 9 | 2024 | 18735 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2015 | 52 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2018 | 524 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2076 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 480 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 644 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 99 | 0.120 |
Why?
|
| Time Factors | 2 | 2014 | 6168 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12020 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 112 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 110 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 177 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 142 | 0.110 |
Why?
|
| Arterial Pressure | 1 | 2014 | 103 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2024 | 3301 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 203 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 349 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2014 | 220 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 237 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2014 | 667 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 319 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1145 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 440 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1407 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 560 | 0.080 |
Why?
|
| Incidence | 3 | 2023 | 3004 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 2524 | 0.080 |
Why?
|
| Portal Pressure | 1 | 2008 | 5 | 0.080 |
Why?
|
| Decision Trees | 1 | 2008 | 48 | 0.080 |
Why?
|
| Hepatic Veins | 1 | 2008 | 23 | 0.080 |
Why?
|
| Sclerotherapy | 1 | 2008 | 40 | 0.070 |
Why?
|
| Ligation | 1 | 2008 | 134 | 0.070 |
Why?
|
| Age Factors | 1 | 2014 | 2774 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 97 | 0.070 |
Why?
|
| Biomarkers | 3 | 2024 | 2939 | 0.070 |
Why?
|
| Esophagoscopy | 1 | 2008 | 150 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2008 | 121 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2024 | 15856 | 0.070 |
Why?
|
| Prothrombin | 1 | 2024 | 24 | 0.060 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2024 | 13 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2024 | 46 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3228 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2024 | 155 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 35 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2024 | 150 | 0.060 |
Why?
|
| Adolescent | 3 | 2020 | 18929 | 0.050 |
Why?
|
| North America | 1 | 2024 | 234 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 332 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 13781 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 1293 | 0.050 |
Why?
|
| Texas | 2 | 2020 | 3513 | 0.050 |
Why?
|
| Adult | 3 | 2018 | 28676 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 313 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 2811 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 122 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 4984 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 210 | 0.040 |
Why?
|
| Keratin-18 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 1992 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 214 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 45 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 214 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 235 | 0.040 |
Why?
|
| Child | 2 | 2015 | 24049 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 421 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2020 | 190 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 312 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1424 | 0.030 |
Why?
|
| Triglycerides | 1 | 2019 | 547 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 41 | 0.030 |
Why?
|
| Creatinine | 1 | 2018 | 379 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 319 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2571 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1560 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 382 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1235 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 540 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1467 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 278 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1391 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1403 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3609 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1997 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4633 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6291 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 8772 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4484 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2997 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8096 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 12304 | 0.010 |
Why?
|